Cargando…

Natural Product 2-Oxokolavenol Is a Novel FXR Agonist

Acetaminophen (APAP) toxicity is a common cause of hepatic failure, and the development of effective therapy is still urgently needed. Farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, has been identified as a master gene for regulating enterohepatic metabolic homeostasis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Fusheng, Gao, Yihui, Li, Xiaobao, Lei, Xiaoguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786051/ https://www.ncbi.nlm.nih.gov/pubmed/36558100 http://dx.doi.org/10.3390/molecules27248968

Ejemplares similares

Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (−)-Fargesone A as a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening
por: Diao, Yanyan, et al.
Publicado: (2018)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Novel FXR agonist nelumal A suppresses colitis and inflammation-related colorectal carcinogenesis
por: Miyazaki, Tsuneyuki, et al.
Publicado: (2021)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists
por: Zhao, Shizhen, et al.
Publicado: (2021)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Structural Investigation for Optimization of Anthranilic Acid Derivatives as Partial FXR Agonists by in Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2016)

Bile Acids and FXR: Novel Targets for Liver Diseases
por: Stofan, Mary, et al.
Publicado: (2020)

Impact of bile acids on the growth of human cholangiocarcinoma via FXR
por: Dai, Jiaqi, et al.
Publicado: (2011)

Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation
por: Schuster, Daniela, et al.
Publicado: (2011)

Alcoholic liver steatosis in mice is aggravated by low-protein diet and reversed by FXR agonist
por: Lívero, Francislaine Aparecida dos Reis, et al.
Publicado: (2012)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists
por: Miyata, Sachiho, et al.
Publicado: (2021)

Stat3 role in the protective effect of FXR Agonist in parenteral nutrition-associated cholestasis
por: Ghosh, Swati, et al.
Publicado: (2023)

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
por: Lu, Lu, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
por: Badman, Michael K., et al.
Publicado: (2019)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum
por: Grienke, Ulrike, et al.
Publicado: (2011)

An extract from date palm fruit (Phoenix dactylifera) acts as a co-agonist ligand for the nuclear receptor FXR and differentially modulates FXR target-gene expression in vitro
por: Alfaro-Viquez, Emilia, et al.
Publicado: (2018)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Selective targeting of nuclear receptor FXR by avermectin analogues with therapeutic effects on nonalcoholic fatty liver disease
por: Jin, Lihua, et al.
Publicado: (2015)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020)

Structural Studies of the Tandem Tudor Domains of Fragile X Mental Retardation Related Proteins FXR1 and FXR2
por: Adams-Cioaba, Melanie A., et al.
Publicado: (2010)

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Insights on FXR selective modulation. Speculation on bile acid chemical space in the discovery of potent and selective agonists
por: Sepe, Valentina, et al.
Publicado: (2016)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion
por: Fan, Yichao, et al.
Publicado: (2017)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Editorial note: repurposing FDA approved drugs as FXR agonists: a structure based in silico pharmacological study
Publicado: (2022)

Reconstruction of FXR Beam Conditions
por: Nexsen, W E, et al.
Publicado: (2001)

Comparative Behavioral Phenotypes of Fmr1 KO, Fxr2 Het, and Fmr1 KO/Fxr2 Het Mice
por: Saré, Rachel Michelle, et al.
Publicado: (2019)

Role of FXR in Renal Physiology and Kidney Diseases
por: Guo, Yanlin, et al.
Publicado: (2023)

Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
por: Correia, Jorge C., et al.
Publicado: (2015)

FXR and NASH: an avenue for tissue-specific regulation
por: Henry, Zakiyah, et al.
Publicado: (2023)

Fatty liver diseases, bile acids, and FXR
por: Zhu, Yan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8a4gp22scfalqu3h91lis8fo9a